Open-Source Rx Value Model Designed To Encourage 'More Productive' Discussions
Industry-funded Open-Source Value Project aims to disseminate tools to the marketplace for customized value assessments, as opposed to offering a specific estimate of value for pricing and coverage decisions.
You may also be interested in...
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.
Institute for Clinical and Economic Review launching pilot program that allows drug assessment models to be inspected, but not manipulated, by manufacturers.
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.